Kevin E. Noonan

home / authors / kevin-e-noonan-0

Kevin E. Noonan, PhD, is a partner at McDonnell Boehnen Hulbert & Berghoff LLP.

Articles

Protecting Intellectual Property for COVID-19 Innovations

Kevin E. Noonan

November 6th 2020

Opposition to IP protection for COVID-19 vaccines, therapies, tests and other technologies may only prevent eradication and treatment of the disease.

Biosimilar Names Prove Difficult to Define

Biosimilar Names Prove Difficult to Define

Kevin E. Noonan

A controversial naming convention attempts to explain important distinctions between biologic drugs and their biosimilar counterparts.

Latest Updated Articles

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

Published: September 11th 2024 | Updated: September 18th 2024

CPHI Pharma Award Finalists Announced for 2024

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

Published: March 27th 2024 | Updated: June 28th 2024

AbbVie Acquires Landos Biopharma and Gets Full FDA Nod for ADC Product

Published: October 28th 2024 | Updated: November 22nd 2024

Discovery to Commercialization: The Right Partnerships are Key to Streamlined Drug Development

Published: November 15th 2024 | Updated: November 22nd 2024

Solving Challenges with AAV Aggregate Analysis Using a Novel Size Exclusion Particle to Determine CQAs

Published: October 28th 2024 | Updated: November 22nd 2024

Cell-based phenotypic screening with Incucyte® Live-Cell Analysis Systems

Optimizing cGMP Facility Design Space with a Hybrid Approach

Published: October 22nd 2024 | Updated: November 22nd 2024

Optimizing cGMP Facility Design Space with a Hybrid Approach

Editorial Information

Do Not Sell My Personal Information

Terms and Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.